Eledon Pharmaceuticals, Inc. (ELDN) has a consensus analyst rating of Buy, based on 4 analysts covering the stock. Of those, 4 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for ELDN is $5.00, representing a +56.3% upside from the current price of $3.2. Price targets range from a low of $5.00 to a high of $5.00.
